On July 9th, the Swiss Drug Maker Novartis received approval from the American Food and Drug Administration to begin selling its Exelon skin patch used to treat Alzheimer’s. The patch will be the first alternative to the already available oral capsule for those who suffer from the debilitating disease.
Doctor George Grossberg, MD, at St. Louis University in St. Louis, Missouri said, "The unique delivery system helps both the patient and the caregiver by providing a much easier way to manage their therapy."
According to initial clinical study data, the patch was the preferred means of delivering medication by 70% of doctors and nurses because it was easier for the patients to follow and use in everyday life and remain on the planned treatment regiment.
James Shannon, head of development at Novartis said, “Innovation isn't just about developing new compounds, but also about meeting therapeutic needs by taking existing knowledge and applying it in new ways. Exelon Patch addresses an important medical need by delivering a proven drug in an entirely new form that meets the needs of patients and their caregivers.”
Alzheimer’s disease is a progressive degenerate disease that alters the brain and causes impared thinking, memory, and behavior. More than 18 million people worldwide suffer from the disease, 5 million in the US alone.
Visit this Consumer Advocacy website for more information on ordering from an online Mexican pharmacy.